Sign in

Private company

BELLICUM PHARMACEUTICALS, INC

Pharmaceutical preparations company1

In its 2023 annual report the company says: “We are a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Our proprietary Chemical Induction of Dimerization, or CID, technology platform is designed to enable control of components of the immune system in real time.”60 It is headquartered in Houston, Texas.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersHouston, Texas1
  • Business address3730 Kirby Drive, Suite 1200, Houston, Tx 770982
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1798.7%Operating margin3
-1664.9%Net margin3
-75.8%Revenue growth, 20223
-1239.4%Return on equity3
-$25.8MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$22.8M
  • Income tax0¢$2.0K

Out of $1.5M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$1.5M in 2022+287% since 2016
0$2.0M$4.0M$6.0M$8.0M2016: $388.0K$388.0K20162017: $185.0K$185.0K2017−52%2018: $1.1M$1.1M2018+505%2019: $7.1M$7.1M2019+538%2020: $500.0K$500.0K2020−93%2021: $6.2M$6.2M2021+1140%2022: $1.5M$1.5M2022−76%
Operating income456783-$27.0M in 2022−61% since 2016
-$100.0M-$75.0M-$50.0M-$25.0M02016: -$68.4M-$68.4M20162017: -$87.4M-$87.4M2017+28%2018: -$95.5M-$95.5M2018+9%2019: -$87.4M-$87.4M2019−8%2020: -$51.7M-$51.7M2020−41%2021: -$24.9M-$24.9M2021−52%2022: -$27.0M-$27.0M2022+9%
Net income456783-$25.0M in 2022−64% since 2016
-$150.0M-$100.0M-$50.0M02016: -$69.2M-$69.2M20162017: -$91.8M-$91.8M2017+33%2018: -$98.0M-$98.0M2018+7%2019: -$112.5M-$112.5M2019+15%2020: -$7.7M-$7.7M2020−93%2021: -$9.7M-$9.7M2021+26%2022: -$25.0M-$25.0M2022+157%
Fiscal year2016201720182019202020212022
Revenue$388.0K4$185.0K5$1.1M6$7.1M7$500.0K7$6.2M3$1.5M3
Cost of revenue$864.0K5$436.0K5
Research and development$51.3M4$65.7M5$71.6M6$64.5M7$39.1M8$23.6M3$22.8M3
Operating expenses$30.6M3$28.5M3
Operating income-$68.4M4-$87.4M5-$95.5M6-$87.4M7-$51.7M8-$24.9M3-$27.0M3
Interest$1.8M4$3.7M5$4.2M6$4.3M7$2.7M8$4.0K8
Income tax$03$2.0K3
Net income-$69.2M4-$91.8M5-$98.0M6-$112.5M7-$7.7M8-$9.7M3-$25.0M3
Earnings per share-$1.348-$0.843-$0.813
Earnings per share (diluted)-$1.348-$0.843-$0.813
Shares (weighted, basic)11.5M shares330.8M shares3
Shares (weighted, diluted)11.5M shares330.8M shares3

Compare BELLICUM PHARMACEUTICALS, INC with another company

Corporate structure

BELLICUM PHARMACEUTICALS, INC sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BELLICUM PHARMACEUTICALS, INC

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G on BELLICUM PHARMACEUTICALS, INC, latest Aug 14, 2025 (5 filings since Feb 15, 2022)
  • Ikarian Capital, LLC Filed SC 13G/A on BELLICUM PHARMACEUTICALS, INC, latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • BAKER BROS. ADVISORS LP Filed SC 13D/A on BELLICUM PHARMACEUTICALS, INC, latest Nov 24, 2023 (2 filings since May 5, 2023)
  • VANGUARD GROUP INC Filed SC 13G/A on BELLICUM PHARMACEUTICALS, INC, latest Feb 9, 2023 (2 filings since Feb 9, 2022)
  • BELLICUM PHARMACEUTICALS, INC Houston, Texas

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BELLICUM PHARMACEUTICALS, INC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$592.0K3 Dec 31, 2022$1.6M3 Dec 31, 2021−63.1%
Accumulated depreciation$570.0K3 Dec 31, 2022$1.6M3 Dec 31, 2021−64.2%
Property and equipment, net$22.0K3 Dec 31, 2022$12.0K3 Dec 31, 2021+83.3%
Operating-lease assets (leased space)$08 Dec 31, 2021$645.0K8 Dec 31, 2020−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$21.8M3 Dec 31, 2022$46.2M3 Dec 31, 2021−52.7%

Leadership

Who has led BELLICUM PHARMACEUTICALS, INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Thomas J. Farrell2014–2017
  2. Richard A. Fair2017–2022

President

  1. Thomas J. Farrell2014–2017
  2. Richard A. Fair2017–2022

Chief financial officer

  1. Alan A. Musso2014–2018
  2. Atabak Mokari2018–2020

Chief operating officer

  1. Annemarie Moseley2014–2017
201520202025
Board members and other officers (25)

Former names

  • BELLICUM PHARMACEUTICALS INCMar 23, 2006 to Jul 29, 20082

Timeline

  1. Feb 23, 20248-K Executive or director change39
  2. Feb 21, 20248-K Completed an acquisition or sale; Shareholder vote40
  3. Jan 30, 20248-K Other events41
  4. Jan 24, 20248-K Unregistered sale of shares; Bylaws or fiscal year changed; Shareholder vote42
  5. Dec 14, 20238-K Regulation FD disclosure43
  6. Nov 22, 20238-K Entered a material agreement44
  7. Sep 29, 20238-K Executive or director change45
  8. Aug 21, 20238-K Regulation FD disclosure46
  9. Jun 2, 20238-K Executive or director change47
  10. May 30, 20238-K Listing notice or transfer48
  11. Apr 11, 20238-K Listing notice or transfer49
  12. Dec 12, 20228-K Bylaws or fiscal year changed50
  13. Feb 1, 2017New chief executive Richard A. Fair becomes CEO12
  14. Dec 17, 2014New chief executive Thomas J. Farrell becomes CEO13

Calendar

When it reported results

  1. Nov 10, 2022Reported quarterly or annual results51
  2. Aug 11, 2022Reported quarterly or annual results52
  3. May 12, 2022Reported quarterly or annual results53
  4. Mar 24, 2022Reported quarterly or annual results54
  5. Nov 4, 2021Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

112 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 23 major events, 30 insider forms, 13 large holders, 36 other. The latest 20:

  1. Aug 14, 2025SCHEDULE 13G EDGAR
  2. Nov 14, 2024SC 13G/A EDGAR
  3. Mar 1, 202415-12G EDGAR
  4. Feb 26, 2024EFFECT EDGAR
  5. Feb 26, 2024EFFECT EDGAR
  6. Feb 26, 2024EFFECT EDGAR
  7. Feb 26, 2024EFFECT EDGAR
  8. Feb 26, 2024EFFECT EDGAR
  9. Feb 26, 2024EFFECT EDGAR
  10. Feb 23, 20248-K EDGAR
  11. Feb 23, 2024POS AM EDGAR
  12. Feb 23, 2024POS AM EDGAR
  13. Feb 23, 2024POS AM EDGAR
  14. Feb 23, 2024POS AM EDGAR
  15. Feb 23, 2024POS AM EDGAR
  16. Feb 23, 2024POS AM EDGAR
  17. Feb 23, 2024S-8 POS EDGAR
  18. Feb 23, 2024S-8 POS EDGAR
  19. Feb 23, 2024S-8 POS EDGAR
  20. Feb 23, 2024S-8 POS EDGAR

The 112 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How BELLICUM PHARMACEUTICALS, INC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBELLICUM PHARMACEUTICALS, INC1
  • CIK0001358403
  • Employer ID (EIN)20-14502001
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address3730 Kirby Drive, Suite 1200, Houston, TX 770981
  • Phone(832) 384-11001
  • Shares outstanding9,716,931 as of Nov 9, 202310
  • Public float$9.2M as of Jun 30, 20223
  • On EDGAR sinceMar 23, 20061
  • Filings611 in all: 4 (234), 8-K (122), 3 (32), 10-Q (27), SC 13G/A (25), CT ORDER (14), EFFECT (13), S-8 (13)1
    All 42 form types

    S-8 POS (13), SC 13G (12), DEF 14A (10), DEFA14A (10), 10-K (9), 424B5 (8), CORRESP (8), UPLOAD (7), POS AM (6), S-3 (6), 4/A (5), D (5), SC 13D (4), SC 13D/A (4), PRE 14A (3), FWP (2), REGDEX (2), 10-K/A (1), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERTNAS (1), D/A (1), DEFR14A (1), DRS (1), REGDEX/A (1), S-1 (1), S-1/A (1), S-1MEF (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Nov 14, 2023
    Proxy statement (DEF 14A) Oct 24, 2022
    Latest 8-K (8-K) Feb 23, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60